Year-end Sale % OFF 
Abstract
After publication of the Review article it was brought to our attention that the sentence at the bottom of the
 section entitled Tiotropium bromide must be corrected as follows:
 “Following positive large efficacy and safety trials in asthma, in 2014 the European Medicines Agency has extended the indication of tiotropium Respimat®....
Highlights
Erratum After publication of the Review article it was brought to our attention that the sentence
in 2014 the European Medicines Agency has extended the indication of tiotropium Respimat® at a dose
latter being extended for patients aged
Summary
Erratum After publication of the Review article [1] it was brought to our attention that the sentence at the bottom of the section entitled Tiotropium bromide (pag 5) must be corrected as follows: “Following positive large efficacy and safety trials in asthma, in 2014 the European Medicines Agency has extended the indication of tiotropium Respimat® at a dose of 5 μg once (delivered in two inhalation of 2.5 μg each) to patients with asthma, which was approved in more than 50 countries, including Japan.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
